PROACT: Do ACE Inhibitors Help Prevent Cardiotoxicity in Patients Treated For Breast Cancer or Lymphoma? - report from ACC2024

David Austin, the study's lead author shared his insights on the PROACT trial. Patients who took the ACE inhibitor enalapril while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels at one month after their last chemotherapy dose compared with those who did not take it, according to results from the PROACT study presented during a Late-Breaking Clinical Trial session at ACC.24 in Atlanta. Video: https://medicaldigest.org/scientific-contents/interview:proact-do-ace-inhibitors-help-prevent-cardiotoxicity-patients-treated-breast-cancer-or-lymphoma